Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The earlier, the better for SMA babies. New research shows that infants with spinal muscular atrophy (SMA) who receive disease-modifying therapy within 21 days of birth are far more likely to walk independently and far less likely to develop complications like scoliosis or swallowing difficulties. Experts say even a three-week delay can make a meaningful difference.
The clock starts at birth for SMA treatment
New research presented at the AANEM 2026 annual meeting found that infants with spinal muscular atrophy (SMA) who began disease-modifying therapy (DMT) within 21 days of birth had significantly better outcomes than those who started treatment later. The study drew on caregiver-reported data from the 2025 and 2026 Cure SMA Community Update Surveys, analyzing 139 children aged 2–9 years split into early- and later-treated groups.
The findings are striking: 83% of early-treated children could walk independently, compared to just 35% of those treated later. Historically, children with two SMN2 gene copies — the majority in the early group — were not expected to ever sit or walk on their own without prompt intervention.
By the Numbers:
Why it matters: With newborn SMA screening now available in all 50 states, the infrastructure exists to catch these cases fast — but insurance delays and family education gaps can still slow treatment initiation. This real-world data makes a compelling case for removing those barriers urgently, as even a few weeks' delay can meaningfully alter a child's developmental trajectory.
